All mass spectrometry articles

  • shutterstock_2689037931
    Article

    Improving selectivity in antibody–drug conjugates

    2026-04-06T10:00:00Z

    Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.